Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
Top Cited Papers
- 14 January 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 63 (3), 827-838
- https://doi.org/10.1002/hep.28368
Abstract
Non-alcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolte to hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD. Aim of this multicenter observational prospective study was to assess the clinical features of patients with NAFLD-related HCC (NAFLD-HCC), and to compare them to those of HCV-related HCC. A total of 756 patients with either NAFLD (145) or HCV-related chronic liver disease (611) were enrolled in Secondary Care Italian Centers. Survival was modeled according to clinical parameters, lead time bias and propensity analysis. As compared to HCV, HCC in NAFLD patients had a larger volume, showed more often an infiltrative pattern and was detected outside specific surveillance. Cirrhosis was present in only about 50% of NAFLD-HCC, differently from the near totality of HCV-HCC. Regardless of the tumor stage, the survival was significantly shorter (p=0.017) in patients with NAFLD-HCC, namely 25.5 months (95% CI 21.9-29.1) than with HCV-HCC, 33.7 months (95% CI 31.9-35.4). To eliminate possible confounders, a propensity score analysis was performed, which showed no more significant difference between the two groups. Additionally, the analysis of patients within Milan criteria submitted to curative treatments did not show any difference in survival between NAFLD-HCC and HCV-HCC (respectively 38.6 vs 41.0 months, p=n.s.) Conclusions: NAFLD-HCC and is more often detected at a later tumor stage and could arise also in the absence of cirrhosis. However after patient matching, NAFLD-HCC has a similar survival as compared to HCV-infected patients. Future challenge will be to identify patients with NAFLD who require more stringent surveillance in order to offer the most timely and effective treatment.Keywords
Funding Information
- European Union Seventh Framework Program (FP7/2007-2013)
- Italian Liver Foundation
This publication has 30 references indexed in Scilit:
- Rise and fall of HCV‐related hepatocellular carcinoma in Italy: a long‐term survey from the ITA.LI.CA centresLiver International, 2013
- Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolizationZeitschrift für Krebsforschung und Klinische Onkologie, 2013
- Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and OutcomesAnnals of Surgical Oncology, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal Of Cancer, 2012
- Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysisHepatology, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology, 2005
- A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis CHepatology, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973